USA Approves Third Dose of BioNTech Vaccine

The US Food and Drug Administration (FDA) has put an end to an issue that has been discussed for some time. Taking a new decision for the mRNA-based coronavirus vaccine produced by Pfizer and BioNTech, the institution decided to use the third dose of the vaccine only for a certain segment in line with this decision. With the decision taken, millions of people in the USA will be shot with the third dose of coronavirus vaccine.

In the statements made by the FDA, it was stated that the third dose of coronavirus vaccine can be administered to individuals aged 65 and over and people in the risk group. The issue, which has been the subject of discussions for a while, has been clarified with the research and decision made by the US authorities. The US is expected to start a third dose of vaccination as soon as possible.

The third dose will be administered 6 months after the second dose.

The FDA also gave details about the conditional approval of the third dose of coronavirus vaccine. Accordingly, individuals aged 65 and over in the USA and those in the high-risk group will be vaccinated against the coronavirus 6 months after the second dose. Making a statement about the fate of people in other age groups, the authorities stated that they need more data on the possibility of the third dose of vaccine in more age groups, and that nothing can be said for now.

The USA, one of the countries deeply affected by the epidemic, did not care about the coronavirus during the Donald Trump era. However, Joe Biden, who has the opposite attitude, seems to have vowed to end the pandemic. Because decisions such as keeping the measures at the required level and applying the vaccination obligation to millions of people are a clear indication that the USA is keeping this job tight.